Search
for
Sort by
Research 541–570 of 1000+
- FDA approves label addition for PDE-5 inhibitor
- FDA declines approval of testosterone drug for third time
- FDA vetoes labelling proposals for finasteride, dutasteride
- Retrospective Pharmacotherapeutic Evaluation of Dutasteride not Approved by US FDA for Androgenetic Alopecia in Korea
- Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
- Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches
- Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System (FAERS) With a Focus on Pericardial Effusions
- The Possible Role of Prescribing Medications, Including Central Nervous System Drugs, in Contributing to Male-Factor Infertility (MFI): Assessment of the Food and Drug Administration (FDA) Pharmacovigilance Database
- Repurposing of Linagliptin Similar FDA Approved Drugs as Antidiabetic Agents
- Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical <i>in silico/in vitro</i> screening methods
- The US FDA has approved the marketing of generic finasteride 5mg tablets by Actavis.
- Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
- Unequal Protection Under the Law: Why FDA Should Use Negotiated Rulemaking to Reform the Regulation of Generic Drugs
- Fast-tracked innovation: orforglipron approval under the FDA’s National Priority Voucher program
- Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system
- Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system
- Not Its Crowning Glory: Obstacles for FDA in Regulating Ingested Dietary Supplements Purporting to Prevent Hair Loss
- 112 Post-Finasteride Syndrome – Outcomes of FDA Database
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules
- A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Innovations in skin microphysiological systems for nonclinical testing and FDA modernization
- PD29-07 DRUGS ASSOCIATED THE MOST WITH MALE-FACTOR INFERTILITY: ASSESSMENT OF THE 2010-2020 FOOD AND DRUG ADMINISTRATION (FDA) PHARMACOVIGILANCE DATABASE
- 0557 Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea (OSA): Results from the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS)
- 054 Post Finasteride Syndrome: Guess Who-Demographics from FDA Database
- A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir
- A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System